Yahoo Finance

Jazz Pharmaceuticals (JAZZ) Is Up 27.7% After Ziihera Phase 3 Success in HER2-Positive Gastric Cancer Trial – Has the Bull Case Changed?

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Benzinga.com

Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer

Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...
Pharm Exec

FDA Grants Priority Review to Jazz Pharmaceuticals’ Zanidatamab for Multiple Forms of HER-2 Positive Biliary Tract Cancer

Submission for the FDA approval of zanidatamab was based on promising data from the Phase IIb HERIZON-BTC-01 clinical trial in patients with previously treated, unresectable, locally advanced, or ...
Investing

UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data

On Tuesday, UBS analysts reaffirmed a Buy rating for Jazz Pharmaceuticals stock (NASDAQ:JAZZ) with a price target of $164.00. Currently trading at $108.29, the stock appears undervalued according to ...
BioWorld

Jazz, Zymeworks unveil positive zanidatamab phase III data

A potentially $1.76 billion oncology deal created a little more than three years ago between partners Jazz Pharmaceuticals plc and Zymeworks Inc. now has a more solid direction. New and positive ...